Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ACLY | P53396 | 1/20 | 0.36 |
| ▸ | PYGL | P06737 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14297710 | 0.89 | CYP2C19 (0.41) | CYP2C19NPC1RAB9AMAPTPYGL | |
| SCHEMBL5010646 | 0.88 | CYP2C19 (0.41) | CYP2C19NPC1RAB9AMAPTPYGL | |
| SCHEMBL5010648 | 0.87 | CYP2C19 (0.42) | CYP2C19NPC1RAB9AMAPTPYGL | |
| SCHEMBL14301501 | 0.87 | NPC1 (0.41) | CYP2C19NPC1RAB9AMAPTPYGL | |
| SCHEMBL14587804 | 0.86 | CYP2C19 (0.39) | CYP2C19NPC1RAB9AMAPTPYGL | |
| SCHEMBL5009797 | 0.85 | NPC1 (0.44) | CYP2C19NPC1RAB9AMAPTPOLB | |
| SCHEMBL5010652 | 0.85 | PIK3CD (0.39) | CYP2C19NPC1RAB9AMAPT | |
| SCHEMBL14587795 | 0.84 | KDM4E (0.40) | CYP2C19NPC1RAB9AMAPT | |
| SCHEMBL14587798 | 0.83 | CYP2C19 (0.40) | CYP2C19SCN9ANPC1RAB9AMAPT | |
| SCHEMBL14587791 | 0.83 | RORC (0.40) | CYP2C19NPC1RAB9AMAPTPYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | CYP2C19 517/4885SCN9A 3013/4885NPC1 2838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.